



TOMÁS J. ARAGÓN, M.D., Dr.P.H.
Director and State Public Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



GAVIN NEWSOM
Governor

Office of AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum
Memorandum Number: 2023-10

DATE: JUNE 23, 2023

TO: ADAP AND PRE-EXPOSURE PROPHYLAXIS ASSISTANCE PROGRAM (PREP-AP)
ENROLLMENT WORKERS

SUBJECT: DOXYCYCLINE POST-EXPOSURE PROPHYLAXIS (doxy-PEP) COVERAGE

In April 2023, the California Department of Public Health (CDPH) released [doxy-PEP recommendations](#) for the prevention of bacterial sexually transmitted infections (STIs). Doxycycline is an antibiotic that has activity against a wide range of bacterial infections. Emerging evidence from studies among men who have sex with men (MSM) and transgender women suggest that doxycycline, when taken as a 200mg oral dose within 72 hours of condomless oral, anal, or vaginal sex, significantly reduces the acquisition of chlamydia, gonorrhea, and syphilis.

ADAP and PrEP-AP Coverage:

Doxycycline is available on both the [ADAP](#) and [PrEP-AP](#) formularies. Clinicians may prescribe doxycycline for use as doxy-PEP without any additional authorizations or paperwork. As pharmacy benefits are structured to cover the cost of medications that are dispensed in one month or three-month intervals, it is recommended that clinicians prescribe an adequate amount of doxycycline to meet a patient's anticipated use for 1 – 3 months. Medications can be filled more than once per month in certain situations (e.g., if a patient has lost their medication) but these early refills may result in the need for additional approvals.

ADAP management requests that you share this information with your clinical leadership team and local prescribers.

If you have any questions regarding this memo, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).

Thank you,

Joseph Lagrama,
ADAP Branch Chief
California Department of Public Health